Skip to main content

CORRECTION article

Front. Oncol., 04 January 2022
Sec. Cancer Immunity and Immunotherapy
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.796625

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

This article is a correction to:

  1. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

    1. Read original article
Min YuanMin YuanZhongzheng ZhuZhongzheng ZhuWei MaoWei MaoHui WangHui WangHong QianHong QianJianguo WuJianguo WuXianling Guo*Xianling Guo*Qing Xu*Qing Xu*
  • Department of Oncology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China

A Corrigendum on:
Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

By Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X and Xu Q (2021). Frontiers in Oncology 11, doi: .10.3389/fonc.2021.683502

In the original article, there was an error. The median PFS was incorrectly written as 8.37 months (95% CI: 6.5-10.0 months) in the abstract.

A correction has been made to Abstract, Results, Paragraph 1:

The median PFS was 4.77 months (95% CI: 4.10-5.44 months).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: anlotinib, anti-PD-1 antibody, angiogenesis, immunotherapy, serum cytokine

Citation: Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X and Xu Q (2022) Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. Front. Oncol. 11:796625. doi: 10.3389/fonc.2021.796625

Received: 17 October 2021; Accepted: 06 December 2021;
Published: 04 January 2022.

Edited and reviewed by:

Catherine Sautes-Fridman, INSERM U1138 Centre de Recherche des Cordeliers (CRC), France

Copyright © 2022 Yuan, Zhu, Mao, Wang, Qian, Wu, Guo and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xianling Guo, yiyibaba18@163.com; Qing Xu, xuqingmd@aliyun.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.